Drug stock price trends in emerging markets are tilting

Drug stock price trends in emerging markets are tilting bullish. India’s Sun Pharma surged 5% on strong export growth, closing around ₹1, With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. Though sales of Paxlovid and Comirnaty have stabilized in 2025 after declining significantly in the past two years, their sales are usually weighted toward the second half of the year and are difficult to estimate as they depend on infection rates. There is an element of uncertainty related to COVID sales, and they may decline further in future years. It’s cheap on a P/E basis, with a P/E of just 10. But the earnings picture looks a bit brighter than that of Pfizer. It is expected to grow earnings by 16.7% in 2025. Merck also pays a dividend, for your patience. It yields 3.6%. The S&P Pharmaceuticals Index shows a 1.9% weekly gain, with drug stock price averages climbing on stronger-than-expected Q2 revenue guidance. Amgen (AMGN) at $280.90 reflects growing interest in its cardiovascular pipeline.